MwanzoMOLN • NASDAQ
add
Molecular Partners AG
Bei iliyotangulia
$ 3.75
Bei za siku
$ 3.72 - $ 3.74
Bei za mwaka
$ 3.36 - $ 7.60
Thamani ya kampuni katika soko
144.10M USD
Wastani wa hisa zilizouzwa
elfu 3.66
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 3.99M | -10.05% |
Mapato halisi | -20.40M | -35.25% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.56 | — |
EBITDA | -14.15M | 7.98% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 114.49M | -28.05% |
Jumla ya mali | 124.25M | -27.17% |
Jumla ya dhima | 17.59M | 16.89% |
Jumla ya hisa | 106.66M | — |
hisa zilizosalia | 37.39M | — |
Uwiano wa bei na thamani | 1.32 | — |
Faida inayotokana na mali | -27.70% | — |
Faida inayotokana mtaji | -30.77% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -20.40M | -35.25% |
Pesa kutokana na shughuli | -13.10M | 16.68% |
Pesa kutokana na uwekezaji | 14.97M | 13.85% |
Pesa kutokana na ufadhili | elfu -243.00 | 8.99% |
Mabadiliko halisi ya pesa taslimu | elfu 603.00 | 122.68% |
Mtiririko huru wa pesa | -3.61M | 63.16% |
Kuhusu
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
153
